Table 5.

Changes in 25(OH)D Levels with Regard to Baseline Characteristics of Breast Cancer Patient

	Placebo			Vitamin D			Absolute treatment effect a
	n	Baseline	8 week follow up	pc	n	Baseline	8 week follow up	pc	placebo	Vitamin D	Pb
BMI
<25	7	16±4.3	13.7±3.7	0.14	3	32±3.6	54±18.4	0.061	-2.2±1.3	21.3±5.5	0.001*
25-30	7	14.8±4.7	13.4±4.8	0.5	9	28±3.7	41.5±4.8	0.014	-1.4±2	13.5±4.3	0.013*
≥30	10	12.7±1.7	11.4±2	0.4	11	26.9±3.5	32.9±3.7	0.26	-1.3±1.5	6±0.5	0.19
Ethnicity
Arab	13	14.8±2.8	12.6±2.6	0.13	14	29.3±4.7	45.9±7	0.016	-2.1±1.3	17±5.7	0.009*
fars	11	13.7±2.6	12.7±2.7	0.46	9	27±2.8	33.5±2.8	0.057	-1±1.3	6.4±3	0.04*
Age
≤50	17	14.9±2.2	12±2.1	0.01	13	23.7±2.3	36.2±3.3	0.016	-2.8±0.98	12.4±4.45	0.005*
>50	7	12.9±3.8	14.3±3.8	0.43	10	33.7±4.8	42.7±7	0.079	1.4±1.7	9±4.5	0.14

Values are Mean±SD;

^*p value< 0.05;

^a, Absolute treatment effect is the absolute changes from baseline to follow-up in the treatment group minus the absolute change from baseline to follow-up in the placebo group;

^b, P values for difference between the treatment and placebo groups;

^c, P values for difference between follow-up and baseline visits.